Nebivolol improved heart function in elderly heart failure patients without significantly lowering natriuretic peptide biomarkers, suggesting peptide levels and cardiac improvement don't always move together.
LVEF: 35% → 43%Heart pumping ability improved significantly on nebivolol while natriuretic peptide levels stayed flat
What the researchers found
In this substudy of the SENIORS trial examining 106 elderly heart failure patients, nebivolol did not produce statistically significant changes in natriuretic peptides (NT-proBNP, pro-ANP), cytokines (TNF-α, sFas, sFas-L), or nitric oxide markers (ADMA, SDMA, arginine, citrulline) compared to placebo over 12 months.
However, left ventricular ejection fraction improved significantly in the nebivolol group (from 35% to 43%) compared to placebo (35% to 34%, P=0.01). NT-proBNP showed a non-significant trend toward increase in the nebivolol group (P=0.08), while soluble Fas trended upward in the placebo group (P=0.08).
Why it matters
Natriuretic peptides like NT-proBNP are the most widely used biomarkers for monitoring heart failure severity. This study reveals a surprising disconnect: nebivolol improved heart function (ejection fraction) without lowering natriuretic peptide levels. This challenges the assumption that effective heart failure treatment should always reduce circulating peptide biomarkers and suggests that the relationship between cardiac improvement and peptide levels is more complex than previously thought.
The numbers in context
n=106 enrolled · n=75 with follow-up · LVEF 35%→43% nebivolol vs 35%→34% placebo (P=0.01) · NT-proBNP trend P=0.08 · sFas trend P=0.08 · 12-month follow-up
How the study worked
Prespecified substudy of the SENIORS randomized controlled trial. 106 elderly heart failure patients were enrolled, with 75 completing baseline and at least one follow-up sample. Researchers measured 12 biomarkers at baseline, 6 months, and 12 months, comparing nebivolol to placebo in a double-blind design.
Who was studied
Elderly patients (≥70 years) with heart failure from the SENIORS trial
What this study cannot tell us
Small substudy sample (75 analyzable patients) limited statistical power to detect biomarker changes. The study may have been underpowered for the number of biomarkers tested. Results represent a subset of the larger SENIORS trial and may not reflect the full trial population.
How to read the evidence
This is a prespecified substudy of a large randomized controlled trial (SENIORS), giving it a solid design foundation. However, the small substudy sample of 75 analyzable patients limits its statistical power, and no biomarker changes reached significance. Rated moderate because the RCT design is strong but the substudy was underpowered.
When this study was published
Published in 2014 using data from the SENIORS trial (2002-2004 enrollment). While the trial is older, the fundamental questions about natriuretic peptide biomarker reliability in elderly heart failure patients remain clinically relevant today.
The bigger picture
Natriuretic peptides (BNP and NT-proBNP) are cornerstones of heart failure diagnosis and monitoring. Clinicians increasingly use peptide-guided therapy — adjusting treatment based on whether peptide levels fall. This study raises an important caution: effective treatment can improve cardiac function without reducing peptide biomarker levels, at least in elderly patients. Understanding when and why peptide biomarkers disconnect from clinical improvement is critical for avoiding misguided treatment decisions based on lab values alone.
Questions still open
- Why does cardiac function improve on nebivolol without a corresponding drop in natriuretic peptide levels?
- Should peptide-guided heart failure therapy be adjusted for elderly patients where biomarker responses may differ?
- Would a larger study with more statistical power reveal significant biomarker changes that this small substudy missed?
Common questions
Why didn't natriuretic peptide levels drop even though the heart got stronger?
Does this mean natriuretic peptide blood tests are unreliable for monitoring heart failure?
Read the original research
Effects of nebivolol on biomarkers in elderly patients with heart failure.
International journal of cardiology, 175(2), 253-60
Citation
Taneja, Anil K; Gaze, David; Coats, Andrew J S; Dumitrascu, Dan; Spinarova, Lenka; Collinson, Paul; Roughton, Michael; Flather, Marcus D. (2014). Effects of nebivolol on biomarkers in elderly patients with heart failure.. International journal of cardiology, 175(2), 253-60. https://doi.org/10.1016/j.ijcard.2014.05.018